In particular, ERBB2 has been shown tophosphorylate cyclin-dependent kinase CDK1, increasing theresistance of cancer cells to apoptosis induced by the cytostaticanticancer drug paclitaxel (Vahedi et al., 2015). Here, ERBB2 is linked to cancer.